

Remarks


Claims 1-8 are currently elected. If found to be patentable, claim group III (claim 20) will be rejoined therewith. See paper no. 20040609 at page 4. Claim 20 has been amended to specify the treatment of colon tumors. This is supported at paragraphs [21] and [30] of the application as originally filed.

Claim 7 is rejected as failing to comply with the written description requirement of 35 U.S.C. § 112, second paragraph, because the specification allegedly does not describe what agents can be used for enhancing absorption through intestines. While applicants do not concede that this rejection is correct, in the interest of advancing this application toward allowance, the claim has been canceled.

A speedy rejoinder and allowance is respectfully requested.

Respectfully submitted,

Dated: March 18, 2005
By:
Sarah A. Kagan
Registration No. 32,141
Banner & Witcoff, Ltd.
Customer No. 22907


Sarah A. Kagan
Registration No. 32,141